MedTrace Logo

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

NCT03793985 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-01-07

No results posted yet for this study

Summary

Compare the pharmacokinetic characteristics and safety between CKD-391 tablet and D337, D337 combination

Conditions

  • Hyperlipidemias

Interventions

DRUG

T

CKD-391 40/10mg

DRUG

R

D086 and D337 co-administration

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2018-10-23
Completion
2018-11-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03793985 on ClinicalTrials.gov